What Henry Schein (HSIC) Said on Its Q3 Earnings Call
Henry Schein (HSIC) reported Q3 earnings, noting pressure in discretionary procedures but strong growth in global dental and specialty products. U.S. dental equipment sales rose 1.6%, while global distribution and value-added services increased 3.7%. The company raised its non-GAAP EPS outlook to $5.50-$5.56. Management expects 2026 sales growth of 4.5%-5.5% and high-single-digit adjusted EBITDA growth.
How this was made
The 30-second read
Why it matters
The key tradable update is the raised non-GAAP diluted EPS outlook, supported by tariff-refund recognition and improved underlying operating performance, alongside a CFO transition effective Nov. 4.
Market read
Investors can update 2026 earnings expectations based on the raised non-GAAP EPS range and the stated assumptions behind EBITDA and tax rate.
What to watch
Technology growth is affected by a prior-year Windows 10 end-of-life comparison, so the reversion to H1 pace may not be purely organic.
Background
The piece summarizes management commentary from Henry Schein’s Q3 earnings call, covering segment trends, margins, restructuring, capital allocation, and updated 2026 guidance.
Ticker impact
Henry Schein raised its non-GAAP diluted EPS outlook to $5.50 to $5.56 and guided Q4 tech growth back to H1 pace.
Likely upward bias as the market reprices 2026 earnings power and the assumed contribution from tariff refunds and operating improvements.
The article contains explicit guidance changes (EPS range raised) plus supporting drivers (tariff refunds recognized in Q3, improved operating performance) and a CFO transition that can affect near-term sentiment.
Market effects
Signals resilience in healthcare distribution and continued traction in practice-management and revenue-cycle technology adoption.
Highlights mixed international comparisons, with strength in several countries but difficult Germany comps tied to event timing.
Tariff-refund assumptions and FX stability are reiterated, which can influence how investors model peers’ 2026 earnings sensitivity.
Counterpoint
Guidance improvement may be partially offset by assumptions (no further tariff refunds, stable FX) and by discretionary procedure pressure.
Key entities
- companyHenry Schein
Global healthcare products and services provider for dental and medical professionals; subject of the earnings-call summary.
- executiveRon South
Transitions from CFO to senior advisor.
- executiveEmmanuel Caprais
Becomes CFO effective Nov. 4.
